Strategic IND Support DUCK FLATS Pharma specializes in strategic drug development with emphasis on non-clinical to clinical pharmacology and regulatory packaging to support IND and NDA/CTD approvals, presenting an opportunity to offer end-to-end regulatory readiness services for potential clients seeking expedited approvals.

Partner for Oragenics Recent collaboration with Oragenics to support FDA IND readiness and clinical trial design for concussion programs signals a proven track record in partnering for regulatory strategy and clinical development, opening doors to similar biotech partnerships.

Small Agile Team With a lean team of 2-10 employees, DUCK FLATS can position itself as a flexible, cost-efficient partner for startups and mid-stage biotech firms needing focused expertise without large overhead.

NIMBLE R&D Focus Expertise across mechanism of action, efficacy, and pharmacokinetics enables tailored development plans that align with therapeutic indications, offering a compelling value proposition for clients seeking accelerated and well-regulated development pathways.

Revenue Growth Potential Reported revenue in the $10M–$25M range suggests a scalable model with room to expand services into broader regulatory packages, non-clinical to clinical transitions, and potential risk-sharing or consulting engagements with biotech clients.